-
Key Takeaways from 2023 SOGO
John L. Marshall, M.D., discusses the key takeaways from the 8th Annual School of Gastrointestinal Oncology® (SOGO) and remaining unmet needs for patients with metastatic colorectal cancer (CRC).
Category: News
-
Dr. Marshall Highlights 2023 ASCO Gastrointestinal Cancers Symposium Research
Dr. Marshall discusses the significant and exciting GI Cancer research presented at the 2023 ASCO GI Cancer Symposium.
Category: News
-
Colorectal Cancer in Young People
Dr. John L. Marshall discusses the increasing incidence rates for colorectal cancer in people under the age of 50.
Category: News
-
Nivolumab Plus Cabozantinib Shows Early Promise in Advanced HCC
Dr. Aiwu He discusses early results from her research0- CheckMate 040, nivolumab plus cabozantinib with or without ipilimumab- which showed good clinical activity and survival.
Category: News
-
Antibiotics Can Be Used During Durvalumab Treatment in Biliary Cancer
“People with advanced BTC can safely be treated with antibiotics while benefiting from treatment with durvalumab plus chemotherapy,” lead author Aiwu He, MD, PhD.
Category: News
-
Engineer Credits Proton Therapy with Beating Stomach Cancer
“They have a great team approach at MedStar Georgetown with an oncologist, surgeon, and radiation therapist,” explains Jack. They told me that because of where my tumor was, I was a great candidate for proton therapy instead of standard radiation.”
Category: News
-
Advancements in the treatment of gastrointestinal cancers
What are some recent advancements in targeted treatments for gastrointestinal cancers? Dr. Benjamin Weinberg discusses clinical trials aimed at treating GI cancers more effectively
Category: News
-
Durvalumab Triplet Improves OS Across Biliary Tract Cancer Locations
Dr. Aiwu Ruth He discusses her recent Biliary Tract Cancer Research that was featured in NEJM Evidence
Category: News
-
Medical Costs and Clinical Value: Playing the Long Game
Even as soaring medical costs strain public and private budgets around the world, patients yearn for therapeutic breakthroughs. Game-changing cancer treatments, emerging antiviral agents, and mRNA vaccines are powerful reminders of medical technology’s potential. But insurance premiums and out-of-pocket payments underscore medicine’s financial burden.
Category: News
-
Durvalumab Plus Chemotherapy Maintains OS Benefit in Advanced Biliary Tract Cancer
Dr. Aiwu Ruth He discusses her biliary tract cancer research presented at ESMO GI
Category: News